Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 1.00 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15522678 | 0.86 | HDAC1 (0.74) | HDAC1HDAC8HDAC7HDAC6 | |
| SCHEMBL10094801 | 0.86 | HDAC1 (0.75) | HDAC1HDAC8LTA4HEPHX2NLRP3 | |
| SCHEMBL4579240 | 0.86 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL22190367 | 0.85 | HDAC1 (0.74) | HDAC1HDAC8MMP1HDAC7HDAC6 | |
| SCHEMBL17054179 | 0.81 | HDAC1 (0.69) | HDAC1HDAC8MMP1HDAC7HDAC6 | |
| SCHEMBL8249818 | 0.81 | HDAC1 (0.69) | HDAC1HDAC8HDAC7HDAC6 | |
| SCHEMBL14188102 | 0.81 | HDAC1 (0.68) | HDAC1HDAC8LTA4HEPHX2HDAC7 | |
| SCHEMBL14188237 | 0.80 | HDAC1 (0.67) | HDAC1HDAC8 | |
| SCHEMBL4579115 | 0.80 | HDAC1 (0.67) | HDAC1HDAC8HDAC7HDAC6 | |
| SCHEMBL4578260 | 0.80 | HDAC1 (1.00) | HDAC1HDAC8EPHX2HDAC6CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2014-01-23 | — | — | US | claimed |
| US-8796330-B2 | Inhibitors of histone deacetylase and prodrugs thereof | METHYLGENE INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-8796330-B2 | Inhibitors of histone deacetylase and prodrugs thereof | METHYLGENE INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-8796330-B2 | Inhibitors of histone deacetylase and prodrugs thereof | METHYLGENE INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-8759400-B2 | Histone deacetylase inhibitors for enhancing activity of antifungal agents | METHYLGENE INC. (CA) | 2014-06-24 | — | — | US | disclosed |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2014-01-23 | — | — | US | disclosed |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2014-01-23 | — | — | US | disclosed |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2014-01-23 | — | — | US | disclosed |
| EP-2573069-A2 | Inhibitors of histone deacetylase and prodrugs thereof | MethylGene Inc. (CA) | 2013-03-27 | — | — | EP | disclosed |
| WO-2012021982-A1 | ANTIFUNGAL AGENTS AND USES THEREOF | METHYLGENE INC. (CA) | 2012-02-23 | — | — | WO | disclosed |
| CN-101610996-A | Histone deacetylase inhibitors and prodrugs thereof | METHYLGENE INC (CA) | 2009-12-23 | — | — | CN | disclosed |
| EP-1973872-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | Methylgene, Inc. (CA) | 2008-10-01 | — | — | EP | disclosed |
| WO-2008074132-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| WO-2008021944-A2 | POTENTIATION OF ANTIFUNGAL COMPOUNDS | METHYLGENE INC. (CA) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007072179-A2 | HISTONE DEACETYLASE INHIBITORS FOR ENHANCING ACTIVITY OF ANTIFUNGAL AGENTS | METHYLGENE, INC. (CA) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC8 9/4885LTA4H 1675/4885 |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC8 9/4885LTA4H 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.